The document discusses strategies for combating counterfeit drugs in the pharmaceutical industry. It mentions that the global sale of counterfeit drugs was estimated at $75 billion in 2010, a 92% increase over 5 years. Various government and industry initiatives to tackle the problem are discussed, such as using holographic labels, mobile authentication services, and barcodes. However, the document argues that more still needs to be done, and that combating counterfeits should be a key part of brand strategy and planning for pharmaceutical companies.